SI2074123T1 - Nove anksiolitične spojine - Google Patents

Nove anksiolitične spojine

Info

Publication number
SI2074123T1
SI2074123T1 SI200731109T SI200731109T SI2074123T1 SI 2074123 T1 SI2074123 T1 SI 2074123T1 SI 200731109 T SI200731109 T SI 200731109T SI 200731109 T SI200731109 T SI 200731109T SI 2074123 T1 SI2074123 T1 SI 2074123T1
Authority
SI
Slovenia
Prior art keywords
anxiolytic compounds
novel anxiolytic
novel
compounds
anxiolytic
Prior art date
Application number
SI200731109T
Other languages
English (en)
Inventor
Jonathan Bayldon Baell
Brad Sleebs
Bernard Luke Flynn
Ian Phillip Street
Nurul Quazi
Chinh Thien Bui
Original Assignee
Bionomics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Limited filed Critical Bionomics Limited
Publication of SI2074123T1 publication Critical patent/SI2074123T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200731109T 2006-10-16 2007-10-16 Nove anksiolitične spojine SI2074123T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85198306P 2006-10-16 2006-10-16
EP07815371A EP2074123B1 (en) 2006-10-16 2007-10-16 Novel anxiolytic compounds
PCT/AU2007/001566 WO2008046135A1 (en) 2006-10-16 2007-10-16 Novel anxiolytic compounds

Publications (1)

Publication Number Publication Date
SI2074123T1 true SI2074123T1 (sl) 2013-03-29

Family

ID=39313499

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731109T SI2074123T1 (sl) 2006-10-16 2007-10-16 Nove anksiolitične spojine

Country Status (13)

Country Link
US (7) US8293737B2 (sl)
EP (2) EP2540722B1 (sl)
JP (4) JP5373613B2 (sl)
AU (1) AU2007312936B2 (sl)
CA (2) CA2666219C (sl)
DK (1) DK2074123T3 (sl)
ES (1) ES2399071T3 (sl)
HK (1) HK1132268A1 (sl)
NZ (1) NZ576036A (sl)
PL (1) PL2074123T3 (sl)
PT (1) PT2074123E (sl)
SI (1) SI2074123T1 (sl)
WO (1) WO2008046135A1 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5373613B2 (ja) 2006-10-16 2013-12-18 バイオノミクス リミテッド 新規な抗不安薬化合物
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
WO2012116410A1 (en) * 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
CA2828780A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
US9133188B2 (en) 2011-05-12 2015-09-15 Bionomics Limited Methods for preparing naphthyridines
WO2014036595A1 (en) * 2012-09-04 2014-03-13 Bionomics Limited Compounds and methods for treating diseases or conditions associated with the central nervous system and/or neurite outgrowth
US9745296B2 (en) 2013-03-15 2017-08-29 Bionomics Limited Salts, co-crystals, and polymorphs of an anxiolytic compound
AU2013204159B2 (en) * 2013-03-15 2015-05-07 Bionomics Limited A Crystalline Form of an Anxiolytic Compound
WO2019109150A1 (en) * 2017-12-07 2019-06-13 Bionomics Limited Methods of treating agitation
EP3867252B1 (en) * 2018-10-18 2023-12-06 Bionomics Limited 6-indan-2-yloxy-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one derivatives and similar compounds as modulators of the alpha 7 nicotinic acetylcholine receptor for the treatment of anxiety
MX2022003347A (es) * 2019-09-23 2022-04-11 Bionomics Ltd Formulaciones terapeuticas y usos de las mismas.

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022214A (en) * 1963-01-31 1966-03-09 Sterling Drug Inc Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
US3429887A (en) * 1965-01-26 1969-02-25 Sterling Drug Inc 1,7-naphthyridine-3-carboxylic acid derivatives and their preparation
US3506668A (en) * 1965-01-26 1970-04-14 Sterling Drug Inc Method of preparing 8-hydroxy-quinolines
JPS5023036B1 (sl) 1970-12-29 1975-08-05
JPS5023037B1 (sl) 1970-12-29 1975-08-05
JPS5023037A (sl) 1973-07-03 1975-03-12
JPS5023036A (sl) * 1973-07-06 1975-03-12
JPS5132594A (en) * 1974-09-11 1976-03-19 Kanebo Ltd 1 88 nafuchirijinjudotai no seiho
JPS5331690A (en) * 1976-09-01 1978-03-25 Shionogi & Co Ltd Oxadithiacephalosporins
JPS54163596A (en) * 1978-06-09 1979-12-26 Daiichi Seiyaku Co Flonaphlizine derivative
JPS55111486A (en) * 1979-02-19 1980-08-28 Dai Ichi Seiyaku Co Ltd Preparation of pro 3,2,-b -1,8-naphthyridine derivative
JPS55151584A (en) * 1979-05-11 1980-11-26 Dai Ichi Seiyaku Co Ltd Preparation of 1,8-naphthyridine derivative
JPS56115787A (en) * 1980-02-19 1981-09-11 Dai Ichi Seiyaku Co Ltd Preparation of furo (3,2-b)(1,8)naphthyridine derivative
JPS56118081A (en) * 1980-02-22 1981-09-16 Dai Ichi Seiyaku Co Ltd Preparation of 6-methoxy-1,8-naphthyridine
JPS56118083A (en) * 1980-02-22 1981-09-16 Dai Ichi Seiyaku Co Ltd Furo(3,2-b)(1,8)naphthyridine derivative
JPS5726688A (en) * 1980-07-24 1982-02-12 Dai Ichi Seiyaku Co Ltd Furo 3,2-b 1,8-naphthyridine-7-carboxylic acid derivative
JPS57109790A (en) * 1980-12-26 1982-07-08 Dai Ichi Seiyaku Co Ltd Furo(3,2-b)1,8-naphthyridine-7-carboxylic acid derivative
US4404201A (en) 1981-11-13 1983-09-13 Warner-Lambert Company Cephalosporins
JPS5993080A (ja) * 1982-11-18 1984-05-29 Sumitomo Chem Co Ltd １，５−ナフチリジンカルボン酸誘導体
ATE113953T1 (de) * 1988-05-10 1994-11-15 Ici Plc Cephalosporine, verfahren zu ihrer herstellung und pharmazeutische präparate.
US5095015A (en) * 1990-07-24 1992-03-10 Neurogen Corporation Certain azacycloalkyl imidazopyrimidines; a new class of gaba brain receptor ligands
US5182386A (en) * 1991-08-27 1993-01-26 Neurogen Corporation Certain imidazoquinoxalinones; a new class of gaba brain receptor ligands
US5182290A (en) * 1991-08-27 1993-01-26 Neurogen Corporation Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
IT1251202B (it) * 1991-09-13 1995-05-04 Mediolanum Farmaceutici Spa 6-amminochinoloni, sintesi ed impiego come antibatterici
US5212310A (en) * 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5306819A (en) * 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
US5750702A (en) * 1993-10-27 1998-05-12 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
US5804686A (en) * 1996-01-19 1998-09-08 Neurogen Corporation fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US6211365B1 (en) * 1996-01-19 2001-04-03 Neurogen Corporation Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US6013650A (en) * 1996-03-14 2000-01-11 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
WO1997034870A1 (en) * 1996-03-22 1997-09-25 Neurogen Corporation Certain fused pyrrolecarboxamides as gaba brain receptor ligands
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
BR9811362A (pt) * 1997-08-25 2000-08-22 Neurogen Corp Composto
US6143760A (en) * 1997-08-25 2000-11-07 Neurogen Corporation Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
WO1999043682A1 (en) * 1998-02-26 1999-09-02 Neurogen Corporation 2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives, their preparation and their use as (ant-)agonists for gaba (a) brain receptors
DE19826050A1 (de) 1998-06-12 1999-12-16 Bayer Ag Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester
US6177569B1 (en) * 1998-08-25 2001-01-23 Neurogen Corporation Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
WO2000037471A1 (en) * 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
DE60018274T2 (de) * 1999-05-06 2005-08-04 Neurogen Corp., Branford Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
US6297256B1 (en) * 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
US6511987B1 (en) * 1999-11-12 2003-01-28 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
WO2001092257A1 (en) * 2000-05-26 2001-12-06 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
US6828329B2 (en) * 2000-06-26 2004-12-07 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US6423956B1 (en) * 2000-07-28 2002-07-23 Optical Biopsy Technologies Fiber-coupled, high-speed, integrated, angled-dual-axis confocal scanning microscopes employing vertical cross-section scanning
JP2004506038A (ja) * 2000-08-16 2004-02-26 ニューロゲン　コーポレイション ２，４−置換ピリジン誘導体
US6656941B2 (en) * 2000-09-06 2003-12-02 Neurogen Corporation Aryl substituted tetrahydroindazoles
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
AUPR283801A0 (en) 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
JP2004527500A (ja) * 2001-03-01 2004-09-09 ファイザー・プロダクツ・インク 認識障害の治療のためのニコチン受容体部分アゴニスト、エストロゲン、選択的エストロゲン調節剤又はビタミンｅとｇａｂａａ逆アゴニストの併用
US6703393B2 (en) * 2001-03-27 2004-03-09 Neurogen Corporation (Oxo-pyrazolo[1,5a]pyrimidin-2-yl) alkyl-carboxamides
EP1450801A4 (en) 2001-11-27 2010-10-27 Merck Sharp & Dohme 2-AMINOQUINOLINE COMPOUNDS
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOQUINOLINE COMPOUNDS
MXPA04011156A (es) * 2002-05-14 2005-02-17 Univ California Acidos quinoloncarboxilicos sustituidos, sus derivados, sitio de accion y usos de los mismos.
IS7839A (is) 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
TW200427688A (en) 2002-12-18 2004-12-16 Glaxo Group Ltd Antibacterial agents
JP2005162726A (ja) * 2003-01-24 2005-06-23 Tanabe Seiyaku Co Ltd ピラゾロピリミジン化合物およびその製法
TW200418835A (en) 2003-01-24 2004-10-01 Tanabe Seiyaku Co A pyrazolopyrimidine compound and a process for preparing the same
US20050031652A1 (en) 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
WO2004083207A1 (en) * 2003-03-12 2004-09-30 Abbott Laboratories Naphthyridine derivatives as antibacterial agents
US7470706B2 (en) * 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7402674B2 (en) * 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004004972B3 (de) 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Heterocyclisch substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004004971B3 (de) 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7498341B2 (en) * 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
BRPI0507309A (pt) * 2004-01-31 2007-06-26 Sanofi Aventis Deutschland derivados de ácido 7-fenilamino-4quinolon-3-carboxìlico, processos para produção e seu uso como medicamento
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
WO2006048146A1 (en) 2004-11-01 2006-05-11 F. Hoffmann-La Roche Ag Quinoline as allosteric enhancers of the gaba-b receptors
CA2589629A1 (en) 2004-12-03 2006-06-29 Merck & Co., Inc. Quinoline tachykinin receptor antagonists
KR100978954B1 (ko) 2005-06-02 2010-08-30 에프. 호프만-라 로슈 아게 Ｇａｂａ-ｂ 증강인자로서 3-메테인설폰일퀴놀린
BRPI0616457A2 (pt) 2005-09-29 2011-06-21 Sanofi Aventis derivados de fenil-1,2 oxadiazolona com grupo fenila, bem como seu uso, composição farmacêutica compreendendo os mesmos e seu processo de preparação
WO2008021210A2 (en) 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
JP5373613B2 (ja) 2006-10-16 2013-12-18 バイオノミクス リミテッド 新規な抗不安薬化合物
AR076687A1 (es) 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
BR112013019683B1 (pt) 2011-02-07 2022-04-19 Biogen Inc Compostos que modulam s1p, composição farmacêutica, e uso dos mesmos
WO2012116410A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
CA2828780A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
US9133188B2 (en) 2011-05-12 2015-09-15 Bionomics Limited Methods for preparing naphthyridines

Also Published As

Publication number Publication date
US20100105678A1 (en) 2010-04-29
US8551990B2 (en) 2013-10-08
JP2013189453A (ja) 2013-09-26
EP2540722B1 (en) 2016-06-08
JP2017105818A (ja) 2017-06-15
EP2074123A1 (en) 2009-07-01
EP2074123A4 (en) 2011-09-07
ES2399071T3 (es) 2013-03-25
JP2015155444A (ja) 2015-08-27
WO2008046135A1 (en) 2008-04-24
AU2007312936B2 (en) 2013-09-26
CA2666219C (en) 2017-02-07
JP6138191B2 (ja) 2017-05-31
US20180105524A1 (en) 2018-04-19
JP5373613B2 (ja) 2013-12-18
US9573945B2 (en) 2017-02-21
NZ576036A (en) 2010-10-29
US8906912B2 (en) 2014-12-09
AU2007312936A1 (en) 2008-04-24
JP2010506829A (ja) 2010-03-04
PL2074123T3 (pl) 2013-04-30
EP2540722A1 (en) 2013-01-02
US9975892B2 (en) 2018-05-22
PT2074123E (pt) 2013-01-22
US8293737B2 (en) 2012-10-23
JP5739476B2 (ja) 2015-06-24
US8614212B2 (en) 2013-12-24
US20170183347A1 (en) 2017-06-29
US20130012509A1 (en) 2013-01-10
CA2954376C (en) 2019-06-11
US10233181B2 (en) 2019-03-19
CA2954376A1 (en) 2008-04-24
HK1132268A1 (en) 2010-02-19
EP2074123B1 (en) 2012-12-05
US20150166534A1 (en) 2015-06-18
DK2074123T3 (da) 2013-01-14
CA2666219A1 (en) 2008-04-24
JP6506322B2 (ja) 2019-04-24
US20140045839A1 (en) 2014-02-13
US20130012508A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
HK1132268A1 (en) Novel anxiolytic compounds
EP2034838A4 (en) NOVEL CONNECTIONS
EP2032142A4 (en) NOVEL CONNECTIONS
EP1981596A4 (en) NEW CONNECTIONS
GB0603550D0 (en) Novel compounds
EP1981900A4 (en) NEW COMPOUNDS
GB0605462D0 (en) Novel compounds
GB0602900D0 (en) Novel Compounds
EP2031965A4 (en) NEW COMPOUNDS
GB0607840D0 (en) Novel compounds
GB0600483D0 (en) Novel compounds
GB0608452D0 (en) Novel compounds
GB0607892D0 (en) Novel compounds
GB0624901D0 (en) Novel compounds E
GB0608299D0 (en) Novel Compounds
GB0607896D0 (en) Novel compounds
GB0602238D0 (en) Novel compounds
GB0602800D0 (en) Novel Compounds
GB0625457D0 (en) Novel compounds
GB0614787D0 (en) Novel compounds
GB0608978D0 (en) Novel compounds
GB0608976D0 (en) Novel compounds
GB0608567D0 (en) Novel compounds
GB0608566D0 (en) Novel compounds
GB0608457D0 (en) Novel compounds